{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:17:34Z","timestamp":1794831454766,"version":"4.9.1"},"reference-count":126,"publisher":"Elsevier","isbn-type":[{"value":"9780323908870","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/b978-0-323-90887-0.00007-9","type":"book-chapter","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T13:20:12Z","timestamp":1768051212000},"page":"329-344","source":"Crossref","is-referenced-by-count":1,"title":["Immunotherapies on Guillain\u2013Barr\u00e9 syndrome and other acute autoimmune neuropathies"],"prefix":"10.1016","author":[{"given":"Linda W.G.","family":"Luijten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jns.12266","article-title":"Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients","volume":"23","author":"Alessandro","year":"2018","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib2","doi-asserted-by":"crossref","first-page":"e2386","DOI":"10.1212\/WNL.0000000000207282","article-title":"CSF findings in relation to clinical characteristics, subtype, and disease course in patients with Guillain-Barr\u00e9 syndrome","volume":"100","author":"Al-Hakem","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00415-018-9151-x","article-title":"Guillain-Barr\u00e9 syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity","volume":"266","author":"Al-Hakem","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib4","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s40265-020-01418-5","article-title":"Imlifidase: first approval","volume":"80","author":"Al-Salama","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib5","doi-asserted-by":"crossref","first-page":"e16335","DOI":"10.1111\/ene.16335","article-title":"Electrodiagnostic subtyping in Guillain-Barr\u00e9 syndrome patients in the International Guillain-Barr\u00e9 outcome study","volume":"31","author":"Arends","year":"2024","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib6","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain-Barre syndrome","volume":"27 Suppl","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1212\/WNL.0000000000012777","article-title":"Applying propensity score methods in clinical research in neurology","volume":"97","author":"Austin","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib126","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1468-1331.2000.00096.x","article-title":"Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barr\u00e9 syndrome: a pilot study","volume":"7","author":"Bensa","year":"2000","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib127","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00415-005-0958-x","article-title":"Long term disability and social status change after Guillain-Barr\u00e9 syndrome","volume":"253","author":"Bersano","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib9","doi-asserted-by":"crossref","first-page":"e2035","DOI":"10.1212\/WNL.0000000000207900","article-title":"Association between Guillain-Barr\u00e9 syndrome and COVID-19 infection and vaccination: a population-based nested case-control study","volume":"101","author":"Bishara","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00e9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/jnnp-2023-331378","article-title":"Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort","volume":"95","author":"Broers","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib12","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib13","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s00415-011-6042-9","article-title":"Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barr\u00e9 syndrome patients","volume":"258","author":"Caudie","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib14","first-page":"CD001798","article-title":"Plasma exchange for Guillain-Barre syndrome","volume":"2","author":"Chevret","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2147\/CLEP.S154500","article-title":"Adjusting for confounding by indication in observational studies: a case study in traumatic brain injury","volume":"10","author":"Cnossen","year":"2018","journal-title":"Clin Epidemiol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib17","doi-asserted-by":"crossref","first-page":"e781","DOI":"10.1212\/NXI.0000000000000781","article-title":"Guillain-Barr\u00e9 syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing","volume":"7","author":"Dalakas","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib18","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/jns.12194","article-title":"Inhibition of complement in Guillain-Barr\u00e9 syndrome: the ICA-GBS study","volume":"22","author":"Davidson","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/TP.0000000000004689","article-title":"Imlifidase desensitization in HLA-incompatible kidney transplantation: finding the sweet spot","volume":"108","author":"de Weerd","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","article-title":"A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barr\u00e9 syndrome","volume":"46","author":"Diener","year":"2001","journal-title":"Eur Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/mus.21480","article-title":"Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy","volume":"41","author":"Dionne","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/1740774520939938","article-title":"Endpoints for randomized controlled clinical trials for COVID-19 treatments","volume":"17","author":"Dodd","year":"2020","journal-title":"Clin Trials"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib24","first-page":"CD008630","article-title":"Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"1","author":"Doets","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib25","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1212\/WNL.0000000000013139","article-title":"Predicting outcome in Guillain-Barre syndrome: international validation of the modified Erasmus GBS outcome score","volume":"98","author":"Doets","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib26","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/brain\/awy232","article-title":"Regional variation of Guillain-Barre syndrome","volume":"141","author":"Doets","year":"2018","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib28","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib29","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1474-4422(20)30221-0","article-title":"Neurological associations of COVID-19","volume":"19","author":"Ellul","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib30","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1111\/ene.15497","article-title":"Guillain-Barr\u00e9 syndrome and COVID-19: a 1-year observational multicenter study","volume":"29","author":"Filosto","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/brain\/awt285","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of Brighton criteria","volume":"137","author":"Fokke","year":"2014","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib32","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40262-022-01136-z","article-title":"Population pharmacokinetic modelling of intravenous immunoglobulin treatment in patients with Guillain-Barr\u00e9 syndrome","volume":"61","author":"Fokkink","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making \u2013 beyond randomized, controlled trials","volume":"377","author":"Frieden","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib34","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1212\/01.WNL.0000148589.87107.9C","article-title":"Physical training and fatigue, fitness, and quality of life in Guillain-Barr\u00e9 syndrome and CIDP","volume":"63","author":"Garssen","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00415-006-0163-6","article-title":"Residual fatigue is independent of antecedent events and disease severity in Guillain-Barr\u00e9 syndrome","volume":"253","author":"Garssen","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5694\/mja17.00552","article-title":"Predictors of respiratory failure in patients with Guillain-Barre syndrome: a systematic review and meta-analysis","volume":"208","author":"Green","year":"2018","journal-title":"Med J Aust"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib37","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13311-019-00716-5","article-title":"Differentiation between Guillain-Barr\u00e9 syndrome and acute-onset chronic inflammatory demyelinating polyradiculoneuritis \u2013 a prospective follow-up study using ultrasound and neurophysiological measurements","volume":"16","author":"Grimm","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib38","first-page":"1462","article-title":"Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire. Remarques sur les caracteres cliniques etgraphiques des reflexes tendineaux","author":"Guillain","year":"1916","journal-title":"Bull Soc Med Hop Paris"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/00365549509019016","article-title":"Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome","volume":"27","author":"G\u00fcrses","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib40","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","article-title":"Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group","volume":"44","author":"Hadden","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib41","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.410400414","article-title":"Acute motor axonal neuropathy: an antibody-mediated attack on axolemma","volume":"40","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410390512","article-title":"Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy","volume":"39","author":"Hafer-Macko","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000527726","article-title":"Decreased incidence of Guillain-Barr\u00e9 syndrome during the COVID-19 pandemic: a retrospective population-based study","volume":"57","author":"Hafsteinsd\u00f3ttir","year":"2023","journal-title":"Neuroepidemiology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib44","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jclinepi.2003.09.014","article-title":"Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements","volume":"57","author":"Hern\u00e1ndez","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib45","first-page":"CD001446","article-title":"Corticosteroids for Guillain-Barre syndrome","volume":"10","author":"Hughes","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib46","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib47","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain-Barre syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib48","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib49","doi-asserted-by":"crossref","first-page":"e022862","DOI":"10.1136\/bmjopen-2018-022862","article-title":"Small volume plasma exchange for Guillain-Barr\u00e9 syndrome in resource-limited settings: a phase II safety and feasibility study","volume":"8","author":"Islam","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib51","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jns.12209","article-title":"International Guillain-Barre syndrome outcome study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barre syndrome","volume":"22","author":"Jacobs","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib52","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1212\/WNL.51.4.1110","article-title":"The spectrum of antecedent infections in Guillain-Barr\u00e9 syndrome: a case-control study","volume":"51","author":"Jacobs","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib53","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1158\/1535-7163.MCT-17-0108","article-title":"Enzymatic inactivation of endogenous IgG by IdeS enhances therapeutic antibody efficacy","volume":"16","author":"Jarnum","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib54","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib55","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/0883073819826225","article-title":"A novel treatment strategy for severe Guillain-Barr\u00e9 syndrome: zipper method","volume":"34","author":"Kesici","year":"2019","journal-title":"J Child Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib56","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transpl"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib57","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/jnnp.54.11.957","article-title":"Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange","volume":"54","author":"Kleyweg","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib58","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.38.10.1639","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with high-dose gammaglobulin","volume":"38","author":"Kleyweg","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib59","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1212\/WNL.58.4.610","article-title":"Infections and course of disease in mild forms of Guillain-Barr\u00e9 syndrome","volume":"58","author":"van Koningsveld","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barr\u00e9 syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barr\u00e9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.2008.156463","article-title":"Recurrent Guillain-Barr\u00e9 syndrome","volume":"80","author":"Kuitwaard","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib64","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"Jama"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib65","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.it.2022.02.003","article-title":"Guillain-Barr\u00e9 syndrome: expanding the concept of molecular mimicry","volume":"43","author":"Laman","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib66","first-page":"472","article-title":"Notesur la paralysie ascendante aigue","author":"Landry","year":"1859","journal-title":"Gaz Hebd"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib67","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1541-0420.2007.00800.x","article-title":"A class of markov models for longitudinal ordinal data","volume":"63","author":"Lee","year":"2007","journal-title":"Biometrics"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib68","doi-asserted-by":"crossref","first-page":"e0211404","DOI":"10.1371\/journal.pone.0211404","article-title":"Efficient design and analysis of randomized controlled trials in rare neurological diseases: an example in Guillain-Barre syndrome","volume":"14","author":"van Leeuwen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib69","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000200885","article-title":"An international perspective on preceding infections in Guillain-Barre syndrome: the IGOS-1000 cohort","volume":"99","author":"Leonhard","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barre syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib71","first-page":"CD009950","article-title":"Pharmacological treatment for pain in Guillain-Barr\u00e9 syndrome","volume":"2015","author":"Liu","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/jnnp-2022-329937","article-title":"Modified Erasmus GBS Respiratory Insufficiency Score: a simplified clinical tool to predict the risk of mechanical ventilation in Guillain-Barre syndrome","volume":"94","author":"Luijten","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib73","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/brain\/awab279","article-title":"Guillain-Barre syndrome after SARS-CoV-2 infection in an international prospective cohort study","volume":"144","author":"Luijten","year":"2021","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40478-016-0291-x","article-title":"C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy","volume":"4","author":"McGonigal","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib75","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/brain\/awq119","article-title":"Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice","volume":"133","author":"McGonigal","year":"2010","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib76","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 Study Group","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib77","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000445347","article-title":"Fatigue, pain, anxiety and depression in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy","volume":"75","author":"Merkies","year":"2016","journal-title":"Eur Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib78","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.24755","article-title":"Mycoplasma pneumoniae triggering the Guillain-Barre syndrome: a case-control study","volume":"80","author":"Meyer Sauteur","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib79","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1537-2995.2007.01405.x","article-title":"Complications of apheresis in children","volume":"47","author":"Michon","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib80","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/ern.11.182","article-title":"Fisher syndrome: clinical features, immunopathogenesis and management","volume":"12","author":"Mori","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib82","first-page":"69","article-title":"A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barr\u00e9 syndrome","volume":"18","author":"Nomura","year":"2001","journal-title":"Neurol Ther"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib83","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CND.0b013e3181f3dbbf","article-title":"Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barr\u00e9 syndrome: critical reassessment of effectiveness and cost-efficiency","volume":"12","author":"Oczko-Walker","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib84","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/brain\/awg233","article-title":"Bickerstaff\u2019s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barr\u00e9 syndrome","volume":"126","author":"Odaka","year":"2003","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib85","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0140-6736(84)90819-5","article-title":"Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy","volume":"2","author":"Osterman","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib86","first-page":"CD004761","article-title":"Treatment for Fisher syndrome, Bickerstaff\u2019s brainstem encephalitis and related disorders","volume":"2007","author":"Overell","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib87","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/WCO.0000000000000725","article-title":"Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"32","author":"Pascual-Go\u00f1i","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib88","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib90","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrneurol.2017.84","article-title":"Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications","volume":"13","author":"Querol","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib91","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/jnnp-2014-307815","article-title":"Electrophysiological diagnosis of Guillain-Barr\u00e9 syndrome subtype: could a single study suffice?","volume":"86","author":"Rajabally","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib92","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e31820e7b62","article-title":"Recognizing Guillain-Barre syndrome in preschool children","volume":"76","author":"Roodbol","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib93","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/cc10240","article-title":"The added value of ordinal analysis in clinical trials: an example in traumatic brain injury","volume":"15","author":"Roozenbeek","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib94","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib95","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.0b013e3181f88345","article-title":"Pain in Guillain-Barre syndrome: a long-term follow-up study","volume":"75","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib96","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib97","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib98","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/ene.12983","article-title":"How often and when Fisher syndrome is overlapped by Guillain-Barr\u00e9 syndrome or Bickerstaff brainstem encephalitis?","volume":"23","author":"Sekiguchi","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib99","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1212\/WNL.0000000000000577","article-title":"Antibodies to single glycolipids and glycolipid complexes in Guillain-Barr\u00e9 syndrome subtypes","volume":"83","author":"Shahrizaila","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib100","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barre syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib101","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp-2012-302824","article-title":"Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome","volume":"84","author":"Shahrizaila","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5603\/AIT.2013.0002","article-title":"Complications in patients treated with plasmapheresis in the intensive care unit","volume":"45","author":"Szczeklik","year":"2013","journal-title":"Anaesthesiol Intensive Ther"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib103","doi-asserted-by":"crossref","first-page":"10809","DOI":"10.1038\/srep10809","article-title":"Streptococcal IdeS: therapeutic potential for Guillain-Barre syndrome","volume":"5","author":"Takahashi","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib104","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/jns.12398","article-title":"Diagnosis of Guillain-Barr\u00e9 syndrome and validation of the Brighton criteria in Malaysia","volume":"25","author":"Tan","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","article-title":"Efficiency of plasma exchange in Guillain-Barr\u00e9 syndrome: role of replacement fluids","volume":"22","year":"1987","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib106","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410410304","article-title":"Appropriate number of plasma exchanges in Guillain-Barr\u00e9 syndrome","volume":"41","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib107","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome","volume":"35","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib108","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1212\/WNL.0000000000000111","article-title":"Guillain-Barre syndrome associated with preceding hepatitis E virus infection","volume":"82","author":"van den Berg","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib109","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib110","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision","volume":"28","author":"van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib27","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European Academy of Neurology\/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barre syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib111","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib112","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","article-title":"Original research: second IVIg course in Guillain-Barr\u00e9 syndrome with poor prognosis: the non-randomised ISID study","volume":"91","author":"Verboon","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib113","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/jns.12238","article-title":"Prediction of disease progression in Miller Fisher and overlap syndromes","volume":"22","author":"Verboon","year":"2017","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib114","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2016-314862","article-title":"Treatment dilemmas in Guillain-Barre syndrome","volume":"88","author":"Verboon","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib115","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1212\/WNL.0000000000007719","article-title":"Current treatment practice of Guillain-Barre syndrome","volume":"93","author":"Verboon","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib116","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/jnnp-2020-325815","article-title":"Intravenous immunoglobulin treatment for mild Guillain-Barr\u00e9 syndrome: an international observational study","volume":"92","author":"Verboon","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib117","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/practneurol-2014-000937","article-title":"Mimics and chameleons in Guillain-Barr\u00e9 and Miller Fisher syndromes","volume":"15","author":"Wakerley","year":"2015","journal-title":"Pract Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib118","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barre syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib119","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ana.21976","article-title":"Prediction of respiratory insufficiency in Guillain-Barre syndrome","volume":"67","author":"Walgaard","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib120","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib121","unstructured":"Wang RM, Feng AH, Sun WX, et al. (2001) Intravenous immunoglobulin therapy in children with Guillain-Barre syndrome. 16: 223\u2013224."},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib122","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib123","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib124","doi-asserted-by":"crossref","first-page":"e0132011","DOI":"10.1371\/journal.pone.0132011","article-title":"Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS \u2013 a novel therapeutic opportunity","volume":"10","author":"Winstedt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/B978-0-323-90887-0.00007-9_bib125","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","article-title":"Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome","volume":"101","author":"Yuki","year":"2004","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Handbook of Clinical Neurology","Immunotherapies for Neurologic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323908870000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323908870000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:29:58Z","timestamp":1775309398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323908870000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780323908870"],"references-count":126,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-90887-0.00007-9","relation":{},"ISSN":["0072-9752"],"issn-type":[{"value":"0072-9752","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}